Hematology

Journal Club ft. NEJM publications

Questions discussed in this category

Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?

2 Answers available

How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?

2 Answers available

What post-protocol therapies did patients on the BRUIN trial in CLL receive, and how did these therapies impact outcomes?

3 Answers available

How do CLL patients with downstream treatment-resistant mutations such as PLCG2 respond to pirtobrutinib?

Are there other mutations/biomarkers in CLL which may specifically predict for response or resistance to pirtobrutinib?

4 Answers available

Papers discussed in this category

The New England journal of medicine, 2022 Feb 24

Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.

N Engl J Med, 2023 Jul 6

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.

Blood advances, 2023 Jun 27

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.

Blood advances, 2022 Oct 25

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.

The Lancet. Oncology, 2018-01

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

The New England journal of medicine, 2018-03-22

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Blood advances, 2024 Mar 26

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.

Haematologica, 2024 Jun 01

Pirtobrutinib venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison.

Related Topics in Hematology